Glucagon-Like Peptide-1 Promotes Islet Cell Growth and Inhibits Apoptosis in Zucker Diabetic Rats
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
A constant remodeling of islet cell mass mediated by proliferative and apoptotic stimuli ensures a dynamic response to a changing demand for insulin. In this study, we investigated the effect of glucagon-like peptide-1 (GLP-1) in Zucker diabetic rats, an animal model in which the onset of diabetes occurs when the proliferative potential and the rate of β-cell apoptosis no longer compensate for the increased demand for insulin. We subjected diabetic rats to a 2-d infusion of GLP-1 and tested their response to an ip glucose tolerance test. GLP-1 produced a significant increase of insulin secretion, which was paralleled by a decrease in plasma glucose levels (P < 0.001 and P < 0.01, respectively). Four days after the removal of the infusion pumps, rats were killed and the pancreas harvested to study the mechanism by which GLP-1 ameliorated glucose tolerance. Ex vivo immunostaining with the marker of cell proliferation, Ki-67, showed that the metabolic changes observed in rats treated with GLP-1 were associated with an increase in cell proliferation of the endocrine and exocrine component of the pancreas. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling staining, a marker of cellular apoptosis, indicated a reduction of apoptotic cells within the islet as well in the exocrine pancreas in GLP-1-treated rats. Double immunostaining for the apoptotic marker caspase-3 and for insulin showed a significant reduction of caspase-3 expression and an increase in insulin content in GLP-1-treated animals. Finally, staining of pancreatic sections with the nuclear dye 4,6-Diaminidino-2-phenyl-dihydrochloride demonstrated a marked reduction of fragmented nuclei in the islet cells of rats treated with GLP-1. Our findings provide evidence that the beneficial effects of GLP-1 in Zucker diabetic rats is mediated by an increase in islet cell proliferation and a decrease of cellular apoptosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [17]
Citations
Cites
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Pick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., & Polonsky, K. S. (1998) · Diabetes · doi:10.2337/diabetes.47.3.358 · Cited by 551
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Perfetti, R. (2000) · Endocrinology · doi:10.1210/en.141.12.4600 · Cited by 442
Self-citationApoptosis Participates in the Remodeling of the Endocrine Pancreas in the Neonatal Rat
Scaglia, L. (1997) · Endocrinology · doi:10.1210/en.138.4.1736 · Cited by 418
β-Cell Mass Dynamics in Zucker Diabetic Fatty Rats
Finegood, D. T., McArthur, M. D., Kojwang, D., Thomas, M. J., Topp, B. G., Leonard, T., & Buckingham, R. E. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1021 · Cited by 374
Research works printed but not linked: 2
- Nauck, 1993, Normalization of fasting hyperglycemia by exogenous glucagon-like peptide-1 [7–36 amide] in type 2 (non-insulin dependent) diabetic patients, Diabetologia, 36, 741, 10.1007/BF00401145 · DOI · Paper page
- Weibel, 1978, Stereologic methods. In: Practical methods for biologic morphometry, London: Academic Press; vol, 1, 101
Cited by
Items 201–300 of 505
Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits
Nauck, M., & Marre, M. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.1997 · Cited by 38
“Animal studies and in vitro data have suggested that GLP-1 may have a benefi cial effect on pancreatic β-cells by both reducing their destruction via apoptotic pathways and inducing β-cell proliferation.(16,17) HOMA-B is a model for assessing in vivo β-cell function based on FPG and plasma insulin levels.”
BackgroundMovahednasab, M., Dianat‐Moghadam, H., Khodadad, S., Nedaeinia, R., Safabakhsh, S., Ferns, G. A., & Salehi, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01623-w · Cited by 47
Gut: A key player in the pathogenesis of type 2 diabetes?
Muscogiuri, G., Balercia, G., Barrea, L., Cignarelli, A., Giorgino, F., Holst, J. J., Laudisio, D., Orio, F., Tirabassi, G., & Colao, A. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1252712 · Cited by 37
“Administration of GLP-1 was associated with proliferative and antiapoptotic effects in both endocrine and exocrine compartments of the pancreas (Bulotta et al., 2004; Farilla et al., 2002), and significantly reduced apoptotic b cells in experimental diabetes models (Li et al., 2003).”
BackgroundA Simple Matter of Life and Death—The Trials of Postnatal Beta-Cell Mass Regulation
Tarabra, E., Pelengaris, S., & Khan, M. (2012) · International Journal of Endocrinology · doi:10.1155/2012/516718 · Cited by 40
“In summary, exogenous GLP-1 treatment stimulates beta-cell proliferation in multiple rodent species and models of beta-cell mitogenesis.”
BackgroundInfluentialMoritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., & Odaka, H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.11.017 · Cited by 41
“In addition, both peptides exhibit trophic affects on pancreatic islets, helping to maintain β-cell function and physiologic numbers (Farilla et al., 2002; Perfetti and Hui, 2004; Rolin et al., 2002).”
BackgroundAhn, H. Y., Kim, M., Seo, C. R., Yoo, H. J., Lee, S., & Lee, J. H. (2018) · Nutrition and Diabetes · doi:10.1038/s41387-018-0052-y · Cited by 42
Dharmalingam, M., Sriram, U., & Baruah, M. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.77571 · Cited by 39
“GLP-1 has been shown to promote islet cell growth and inhibit apoptosis in vivo in Zucker Diabetic rats, in which the onset of diabetes occurs when the proliferative potential and the rate of β-cell apoptosis no longer compensate for increased insulin demands.[24]”
BackgroundGlucagon-like peptide-1 regulation by food proteins and protein hydrolysates
Miguéns‐Gómez, A., Casanova-Martí, À., Blay, M., Terra, X., Beltrán‐Debón, R., Rodríguez‐Gallego, E., Ardèvol, A., & Pinent, M. (2021) · Nutrition Research Reviews · doi:10.1017/s0954422421000019 · Cited by 41
“tosis in the pancreas of Zucker diabetic rats(12,13).”
Background“The next big thing” in diabetes: clinical progress on DPP‐IV inhibitors
von Geldern, T. W., & Trevillyan, J. M. (2006) · Drug Development Research · doi:10.1002/ddr.20138 · Cited by 40
“Not only does it stimulate b-cell proliferation, it also inhibits apoptosis of b-cells [Farilla et al., 2002].”
BackgroundMega, C., Vala, H., Rodrigues‐Santos, P., de Oliveira, J. B. F., Teixeira, F. J., Fernandes, R., Reis, F., & Teixeira‐Lemos, E. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-42 · Cited by 39
“It could be hypothesized that sitagliptin-evoked increased GLP-1 availability, due to inhibition of its degradation by DPP-IV, will favour the development of new cells, via proliferation enhancement of pre-existing cells and induction of islet neogenesis, effects that were previously reported for GLP-1 [27].”
BackgroundShandilya, A., & Mehan, S. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05328-6 · Cited by 37
“It affectsβ cell proliferation, neurogenesis, and apoptosis trophically [80, 81].”
BackgroundThe importance of β-cell management in type 2 diabetes
Standl, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01360.x · Cited by 40
Triplitt, C. L., McGill, J. B., Porte, D., & Conner, C. S. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.9-c.1 · Cited by 39
“An increase in β-cell mass is observed via inhibition of the process of cellular apoptosis and stimulation of β-cell growth (proliferation and neogenesis).(14,42,54,60,61) Farilla et al.”
Update on the Protective Molecular Pathways Improving Pancreatic Beta-Cell Dysfunction
Puddu, A., Sanguineti, R., Mach, F., Dallegri, F., Viviani, G. L., & Montecucco, F. (2013) · Mediators of Inflammation · doi:10.1155/2013/750540 · Cited by 35
“The recently developed treatment against diabetes, based on GLP-1 receptor agonists or dipeptidyl peptidase-4 (DPP4) inhibitors (the enzyme responsible of GLP-1 inactivation), have been shown to induce beneficial effects on beta cell function [15–21].”
MethodSathanoori, R., Olde, B., Erlinge, D., Göransson, O., & Wierup, N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.437145 · Cited by 39
Kanda, Y., Hashiramoto, M., Shimoda, M., Hamamoto, S., Tawaramoto, K., Kimura, T., Hirukawa, H., Nakashima, K., & Kaku, K. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2014.10.007 · Cited by 32
“neogenesis and inhibit β-cell apoptosis in cultured β cells and in rodent models, thus promoting the expansion of β-cell mass [31–33].”
BackgroundSchou, J. H., Pilgaard, K. A., Vilsbøll, T., Jensen, C. B., Deacon, C. F., Holst, J. J., Vølund, A., Madsbad, S., & Vaag, A. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0382 · Cited by 33
Li, M. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i8.1683 · Cited by 33
Seino, Y., Rasmussen, M. F., Nishida, T., & Kaku, K. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00103.x · Cited by 35
Bariatric surgery for diabetes management
Frachetti, K. J., & Goldfine, A. B. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32832912e7 · Cited by 36
Facilitating Physiologic Self-Regeneration: A Step Beyond Islet Cell Replacement
Rood, P. P. M., Bottino, R., Balamurugan, A. N., Fan, Y., Cooper, D. K. C., & Trucco, M. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-9095-6 · Cited by 33
“factors, like PAX4 (83), HGF (87), IGF-1 (90,91), or GLP-1 (92), the insulin promoter should be used to construct the cassettes eventually introduced into the vector.”
MethodSeino, Y., Inagaki, N., Miyahara, H., Okuda, I., Bush, M., Ye, J., Holland, M. C., JOHNSON, S. L., Lewis, E., & Nakajima, H. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.896327 · Cited by 33
Tatarkiewicz, K., Sablan, E. J., Polizzi, C. J., Villescaz, C., & Parkes, D. G. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00495.2013 · Cited by 31
“Activation of the GLP-1R results in metabolic benefits including enhanced insulin secretion (20, 22, 31), preservation of pancreatic -cells (5, 11, 56), slowing of gastric emptying (GE) (16, 51), glucagon suppression (9, 17), decreased food intake (28, 46), and improved hepatic steatosis (10).”
BackgroundThe Role of GLP-1 in the Regulation of Islet Cell Mass
Bulotta, A., Farilla, L., Hui, H., & Perfetti, R. (2004) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:40:3:65 · Cited by 34
“Recently, when confirming the previously reported observation describing the presence of a very high percentage of apoptotic nuclei in the pancreas of ZDF rats, we found that treatment with GLP-1 drastically reduced the number of apoptotic cells ( 13 ).”
BackgroundResultInfluentialSelf-citationThomas, L. H., Tadayyon, M., & Mark, M. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143966 · Cited by 36
“Furthermore, GLP-1 has been shown to restore -cell mass in rodents by stimulation of -cell neogenesis and proliferation and inhibiting -cell apoptosis (Xu et al., 1999; Tourrel et al., 2001; Farilla et al., 2002; Mu et al., 2006).”
BackgroundHypoglycemia after gastric bypass surgery
Singh, E., & Vella, A. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.4.217 · Cited by 30
Vilsbøll, T., & Garber, A. J. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01579.x · Cited by 30
“Zucker diabetic fatty rats (ZDF) exhibited improved glycaemic control following a 2-day continuous infusion of GLP-1 [27].”
BackgroundTanenberg, R. J., Tanenberg, R. J., & Pories, W. J. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s9981 · Cited by 30
“In addition, it has been shown in animal models with DM2, that GLP-1 increased beta-cell mass through regulation of proliferation, neogenesis, and apoptosis.(7) This last quality of GLP-1 would suggest a hopeful scenario for patients with DM1 of whom their residual beta cell mass is mostly minimal or absent.”
BackgroundVenom peptides as pharmacological tools and therapeutics for diabetes
Robinson, S. D., & Safavi-Hemami, H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.001 · Cited by 33
“Finally, GLP-1 also stimulates pancreatic beta cell proliferation and prevents beta cell death (Farilla et al., 2002), suggesting it can not only prevent, but also perhaps partly reverse some of the complications associated with T2D.”
BackgroundRetnakaran, R. R., Qi, Y., Opsteen, C., Vivero, E. J. A. R., & Zinman, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01254.x · Cited by 30
Novel strategies for the pharmacological management of type 2 diabetes
Nourparvar, A., Bulotta, A., Mario, U. D., & Perfetti, R. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.12.007 · Cited by 34
Self-citationPharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 37
Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder
Brunton, S. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2054 · Cited by 37
“However, in preclinical studies, GLP-1 has demonstrated several effects on pancreatic β-cells that are pertinent to the pathophysiology of type 2 diabetes: it increases proinsulin biosynthesis, increases β-cell proliferation and neogenesis, and decreases β-cell apoptosis.(36,37) Glucagon-like peptide-1 also acts on pa…”
BackgroundTherapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass
Jung, K. Y., Kim, K. M., & Lim, S. K. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.6.426 · Cited by 34
“Islets of Langerhans from GLP-1-treated rats had significantly fewer apoptotic nuclei [38].”
InfluentialGut peptides in the treatment of diabetes mellitus
Vahl, T. P., & D’Alessio, D. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.177 · Cited by 31
“Furthermore, DPP-IV inhibition leads to increased β-cell survival and islet neogenesis in streptozotocin-induced diabetes [172], which is consistent with the effects of GLP-1 receptor agonists in other studies [93,102].”
BackgroundResultSynthesis, Characterization and Pharmacodynamics of Vitamin‐B12‐Conjugated Glucagon‐Like Peptide‐1
Clardy‐James, S., Chepurny, O. G., Leech, C. A., Holz, G. G., & Doyle, R. P. (2012) · ChemMedChem · doi:10.1002/cmdc.201200461 · Cited by 29
Shen, C., Fagan, S. P., Fischman, A. J., Carter, E. E., Chai, J., Lu, X.-M., Yu, Y., & Tompkins, R. G. (2011) · Surgery · doi:10.1016/j.surg.2010.11.017 · Cited by 28
“The safety and efficiency of its clinical applications have been confirmed by recent reports on glucose control in ICU surgical patients [35] and in protection of beta cell function after transplantation [47].”
COUP-TFII Controls Mouse Pancreatic β-Cell Mass through GLP-1-β-Catenin Signaling Pathways
Boutant, M., Ramos, O. H. P., Tourrel-Cuzin, C., Movassat, J., Ilias, A., Vallois, D., Planchais, J., Pégorier, J.-P., Schuit, F., Petit, P. X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030847 · Cited by 28
“There is evidence that GLP-1 can stimulate differentiation of b-cell precursors [48,43] and prevent apoptosis [18,19,20].”
BackgroundVahl, T. P., & D’Alessio, D. A. (2003) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000078991.96795.84 · Cited by 33
Bariatric Surgery in Type 1 Diabetes Mellitus: A Systematic Review
Mahawar, K. K., de Alwis, N. M. W., Carr, W. R. J., Jennings, N., Schroeder, N., & Small, P. K. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1924-z · Cited by 32
In support of an early polypharmacy approach to the treatment of type 2 diabetes
Wright, E. E., Stonehouse, A. H., & Cuddihy, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01255.x · Cited by 27
Brill, A. L., Wisinski, J. A., Cadena, M. T., Thompson, M. F., Fenske, R. J., Brar, H. K., Schaid, M. D., Pasker, R. L., & Kimple, M. E. (2016) · Molecular Endocrinology · doi:10.1210/me.2015-1164 · Cited by 29
2. DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes
Wiedeman, P. E. (2007) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(06)45502-8 · Cited by 28
Exenatide: a novel treatment of Type 2 diabetes
Åhrén, B. (2005) · Therapy · doi:10.2217/14750708.2.2.207 · Cited by 26
“Furthermore, GLP-1 has been shown to inhibit apoptosis in islet cells as evident from a study in which Zucker diabetic fatty (ZDF) rats were treated with GLP-1 [49].”
BackgroundPuddu, A., Storace, D., Durante, A., Odetti, P. R., & Viviani, G. L. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.06.100 · Cited by 28
“GLP-1 is known to improve pancreatic beta cell survival by preventing apoptosis, and the ability of GLP-1 to prevent caspase-3 activation has been described in several previous studies [11,13,16].”
Wang, W., Wu, R., Pin, C., Xu, X., Shi, X. Z., Huang, L. H., Shao, Z. L., & Guo, W. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3212 · Cited by 27
Therapeutic approaches based on beta-cell mass preservation and/or regeneration
Robert, A. R. (2009) · Frontiers in bioscience · doi:10.2741/3345 · Cited by 26
Gene Therapy for Type 1 Diabetes
Giannoukakis, N., & Trucco, M. (2005) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000178774.39149.2d · Cited by 25
Marenah, L., McCluskey, J. T., Abdel‐Wahab, Y. H. A., O'Harte, F. P. M., McClenaghan, N. H., & Flatt, P. R. (2006) · Biological Chemistry · doi:10.1515/bc.2006.118 · Cited by 26
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25
“GLP-1 has been shown to improve pancreatic beta-cell function, delay gastric emptying, promote satiety and confer a protective effect on the cardiovascular system [13-17].”
BackgroundThe anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats
Skarbaliene, J., Secher, T., Jelsing, J., Ansarullah, M., Neerup, T. S. R., Billestrup, N., & Fosgerau, K. (2015) · Peptides · doi:10.1016/j.peptides.2015.03.024 · Cited by 25
“In addition, GLP-1 agonists have been shown to increase pancreatic beta cell mass and glucose sensitivity in rodent models of T2D [7–9].”
BackgroundKaku, K., Kiyosue, A., Ono, Y., Shiraiwa, T., Kaneko, S., Nishijima, K., Bosch‐Traberg, H., & Seino, Y. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12367 · Cited by 27
Lamont, B. J., & Andrikopoulos, S. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0577 · Cited by 29
Combes, J., Borot, S., Mougel, F., & Penfornis, A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01311.x · Cited by 26
“On top of the insulinotropic effects, GLP-1 stimulates insulin production and exerts a trophic effect on β cells (differentiation of progenitor cells, reduction of apoptosis and proliferation of β cells) (figure 3) [81].”
BackgroundPreservation of Beta-Cell Function in Type 2 Diabetes
Nyalakonda, K., Sharma, T., & Ismail‐Beigi, F. (2010) · Endocrine Practice · doi:10.4158/ep10112.ra · Cited by 27
Advances in the surgical treatment of morbid obesity
Stefater, M. A., Kohli, R., & Inge, T. H. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.006 · Cited by 31
Newly Approved and Promising Antidiabetic Agents
Combettes, M., & Kargar, C. (2007) · Therapies · doi:10.2515/therapie:2007054 · Cited by 27
Hata, T., Mera, Y., Kawai, T., Ishii, Y., Kuroki, Y., Kakimoto, K., Ohta, T., & Kakutani, M. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01387.x · Cited by 25
“GLP-1 is known to be able to prevent apoptosis in the pancreatic β cells and stimulate the proliferation and differentiation of insulin-secreting β cells in ZDF rats [19,20].”
BackgroundMize, D. L. E., & Salehi, M. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0377-9 · Cited by 24
Aoki, K., Miyazaki, T., Nagakura, J., Orime, K., Togashi, Y., & Terauchi, Y. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-064 · Cited by 24
Xie, Y., Wang, S., Wei-wei, S. H. A., Zhou, X., Wang, W., Li-pin, H. A. N., Li, D., & Demin, Y. (2008) · Chinese Medical Journal · doi:10.1097/00029330-200811010-00005 · Cited by 24
The spectrum of antidiabetic actions of GLP-1 in patients with diabetes
Vilsbøll, T., Holst, J. J., & Knop, F. K. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.011 · Cited by 25
Kim, Y. K., Joung, K. H., Ryu, M. J., Kim, S. J., Kim, H., Chung, H. K., Lee, M. H., Lee, S. E., Choi, M. J., Chang, J. Y., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3506-y · Cited by 24
“GLP-1 promotes beta cell proliferation and inhibits beta cell apoptosis [34, 35, 47, 48].”
BackgroundNishio, Y., Kimura, H., Tosaki, S., Sugaru, E., Sakai, M., Horiguchi, M., Masui, Y., Ono, M., Nakagawa, T., & Nakahira, H. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.101 · Cited by 24
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 27
“When blood glucose level is low, GLP-1RA have no stimulating effect on insulin secretion, which helps decrease the risk of hypoglycemia (Farilla et al., 2002; Sfairopoulos et al., 2018; Sharma et al., 2018; Sposito et al., 2018).”
BackgroundCharacterization of residual β cell function in long‐standing type 1 diabetes
Sherr, J. L., Ghazi, T., Wurtz, A., Rink, L., & Herold, K. C. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2478 · Cited by 27
Asakawa, M., Mitsui, H., Akihisa, M., Sekine, T., Niitsu, Y., Kobayashi, A., Miyake, A., Hashimoto, N., Kawamura, M., & Ogawa, Y. (2015) · SpringerPlus · doi:10.1186/s40064-015-1135-z · Cited by 25
Fujimoto, S., Mukai, E., & Inagaki, N. (2011) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2011.07.013 · Cited by 24
Miao, X., Gu, Z., Liu, Y., Jin, M., Lu, Y., Gong, Y., Li, L., & Li, C. (2017) · Peptides · doi:10.1016/j.peptides.2017.07.006 · Cited by 24
JNK3 Is Required for the Cytoprotective Effect of Exendin 4
Ezanno, H., Pawlowski, V., Abdelli, S., Boutry, R., Gmyr, V., Kerr-Conte, J. A., Bonny, C., Pattou, F. N., & Abderrahmani, A. (2014) · Journal of Diabetes Research · doi:10.1155/2014/814854 · Cited by 25
“Administration of GLP1 improves beta cell survival in animal model of diabetes [14, 15].”
Li, Y., Wang, Y., Zhang, L., Yan, Z., Shen, J., Chang, Y., & Wang, J. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c06456 · Cited by 22
Svidnicki, P. V., Leite, N. C., Venturelli, A. C., Camargo, R. L., Vicari, M. R., de Almeida, M. C., Artoni, R. F., Nogaroto, V., & Grassiolli, S. (2013) · Acta Physiologica · doi:10.1111/apha.12128 · Cited by 24
Dirksen, C., Jacobsen, S. H., Bojsen-Møller, K. N., Jørgensen, N. B., Naver, L., Hvolris, L., Worm, D., Madsbad, S., Holst, J. J., & Hansen, D. L. (2012) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2012.01.002 · Cited by 22
Coordinated age-dependent and pancreatic-specific expression of mouseReg2Reg3α, andReg3βgenes
Wang, Y., Jacovetti, C., Li, B., Siddique, T., Xiong, X., Yin, H., Wang, M., Zhao, H., & Liu, J. (2011) · Growth Factors · doi:10.3109/08977194.2011.562866 · Cited by 23
“Growth factors such as hepatocyte growth factor and glucagon-like peptide 1 have the potential to increase or sustain b-cell mass under various conditions (Garcia-Ocana et al. 2000; Farilla et al. 2002; Egan et al. 2003).”
BackgroundIncretin-based therapies in type 2 diabetes: A review of clinical results
Bosi, E., Lucotti, P., Setola, E., Monti, L. D., & Piatti, P. M. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.10.003 · Cited by 27
Scott, R., Tan, T., & Bloom, S. R. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-407766-9.00007-9 · Cited by 21
“ation, and reduces cell apoptosis (Drucker, Philippe, Moisoy, Chick, & Habener, 1987; Farilla et al., 2002).”
BackgroundInfluentialSheffield, C. A., Kane, M. P., & Busch, R. S. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.10.1449 · Cited by 21
Freeman, J. S. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0467 · Cited by 24
Nishio, Y., Kimura, H., Sawada, N., Sugaru, E., Horiguchi, M., Ono, M., Furuta, Y., Sakai, M., Masui, Y., Otani, M., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.07.042 · Cited by 21
Fiorentino, T. V., Owston, M. A., ABRAHAMIAN, G. A., Rosa, S. L., Marando, A., Perego, C., Cairano, E. S. D., Finzi, G., Capella, C., Sessa, F., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.09.009 · Cited by 21
Davidson, J. A., Parente, E. B., & Gross, J. L. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000600016 · Cited by 29
“Although not demonstrated in humans, experimental in vivo and in vitro studies have reported that GLP-1 promotes β-cell proliferation and function, induces islet neogenesis and reduces apoptosis (35;36).”
BackgroundSharma, M. C., Jain, S. K., & Sharma, R. (2017) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-017-0163-8 · Cited by 21
“Type 2 diabetes (T2D) known as noninsulin-dependent diabetes mellitus (NIDDM) or adult onset diabetes is caused by pancreas β-cell dysfunction deficiency in insulin secretion (Farilla 2002), insulin resistance, or increased hepatic glucose production.”
Green, B., Liu, H. K., McCluskey, J. T., Duffy, N. A., O'Harte, F. P. M., McClenaghan, N. H., & Flatt, P. R. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00430.x · Cited by 22
Drucker, D. J. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706287651 · Cited by 21
“GLP-1 has also been shown to have beneficial effects on β-cell function in animal models and in human islets studied in vitro.(43,44) Because of these differences, therapies that are based on the actions of GLP-1 are more attractive for the treatment of type 2 diabetes.”
BackgroundMikov, M., Pavlović, N., Stanimirov, B., Đanić, M., Goločorbin-Kon, S., Stankov, K., & Al‐Salami, H. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00570-y · Cited by 25
Sato, K., Nakamura, A., Shirakawa, J., Muraoka, T., Togashi, Y., Shinoda, K., Orime, K., Kubota, N., Kadowaki, T., & Terauchi, Y. (2012) · Endocrinology · doi:10.1210/en.2011-1712 · Cited by 20
Pancreas β cell regeneration and type 1 diabetes (Review)
Wu, J.-X., Yang, X., Chen, B., & Xu, X. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.2163 · Cited by 23
A Novel Resting Strategy for Improving Islet Engraftment in the Liver
Jimbo, T., Inagaki, A., Imura, T., Sekiguchi, S., Nakamura, Y., Fujimori, K., Miyagawa, J., Ohuchi, N., Satomi, S., & Goto, M. (2014) · Transplantation · doi:10.1097/01.tp.0000437557.50261.b9 · Cited by 18
“In general, stimulation of proliferation and inhibition of the apoptosis of beta cells in vivo or in vitro studies are induced by a pharmacological level of GLP-1 analogues with a longer half-life or continuous infusion of GLP-1 (31, 32).”
BackgroundInfluentialAlbiglutide: Is a better hope against diabetes mellitus?
Sharma, A. K., Veeraveedu, P. T., & Rajput, S. K. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.015 · Cited by 19
Aoki, K., Sato, H., & Terauchi, Y. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0041 · Cited by 23
“GLP-1 can reduce appetite and food intake and has a protective effect on the pancreatic β-cell function in animal models [8, 9].”
BackgroundRoles of Hormones in Taste Signaling
Shin, Y., & Egan, J. M. (2010) · Results and problems in cell differentiation · doi:10.1007/978-3-642-14426-4_10 · Cited by 23
Kaviani, M., Keshtkar, S., Azarpira, N., Aghdaei, M. H., Geramizadeh, B., Karimi, M. H., Shamsaeefar, A., Motazedian, N., Nikeghbalian, S., Al-Abdullah, I. H., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108674 · Cited by 18
Shida, T., Kamei, N., Takeda‐Morishita, M., Isowa, K., & Takayama, K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.04.029 · Cited by 18
Furuta, Y., Horiguchi, M., Sugaru, E., Ono‐Kishino, M., Otani, M., Sakai, M., Masui, Y., Tsuchida, A., Sato, Y., Takubo, K., et al. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01180.x · Cited by 19
“DSP-7238, vildagliptin (1-[[(3-hydroxy-1-adamantyl) amino] acetyl]-2-cyano-(S)-pyrrolidine) [14], sitagliptin ((2R)-4-oxo4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazol[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine phosphate) [15], saxagliptin ((1S,3S,5S)-2-[(2S)-2-amino-2 -(3-hydroxy-1-adamantyl)a…”
BackgroundNeprilysin Deficiency Is Associated With Expansion of Islet β-Cell Mass in High Fat-Fed Mice
Parilla, J. H., Hull, R. L., & Zraika, S. (2018) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155418765164 · Cited by 21
“11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides.”
BackgroundInfluentialBae, J., Kim, G., Lee, Y., Lee, B., Kang, E. S., & Soo, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0541-y · Cited by 18
Self-citationReprogramming Cells to Make Insulin
McKimpson, W. M., & Accili, D. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00040 · Cited by 19
Ma, X., Hui, H., Liu, Z., He, G., Hu, J. R., Meng, J., Guan, L., & Luo, X. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01070.x · Cited by 18
Self-citationEffect of PANDER in βTC6-cell lipoapoptosis and the protective role of exendin-4
Xiang, J.-N., Chen, D., & Yang, L. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.04.065 · Cited by 19
Hypoglycemia - Causes and Occurrences
Rigobelo, E. C. (2011) · InTech eBooks · doi:10.5772/864 · Cited by 17
Metadata
- Authors
- Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R.
- Affiliations
- Cedars-Sinai Medical Center (US)
- University of California, Los Angeles (US)
- Corresponding author
- Perfetti, Riccardo
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2002-11-01
- Volume
- 143
- Issue
- 11
- Pages
- 4397-4408
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2063693981
- Cited by
- 502
- References
- 20
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 10 · 2022: 5 · 2021: 17 · 2020: 12 · 2019: 18 · 2018: 12 · 2017: 16 · 2016: 18 · 2015: 25 · 2014: 32 · 2013: 33 · 2012: 33
- FWCI
- 17.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Federation for Aging Research
- Cedars-Sinai Medical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- glucagon-like peptide-1, islet cell proliferation, beta-cell apoptosis, type 2 diabetes, insulin secretion, glucose tolerance, caspase-3, Ki-67, exocrine pancreas, pancreatic islets, nuclear fragmentation
- MeSH terms
- Insulin Secretion, Animals, Blood Glucose, Cell Division, Diabetes Mellitus, Glucagon, Insulin, Islets of Langerhans, Kinetics, Male, Peptide Fragments, Protein Precursors, Rats, Zucker, Apoptosis, Ki-67 Antigen, Caspases, In Situ Nick-End Labeling, Rats, Glucagon-Like Peptide 1, Caspase 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.